Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($2.02), $0.32 worse than the analyst estimate of ($1.70). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.01 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.